Regeneron and sanofi provide regulatory update on libtayo® (cemiplimab-rwlc) in advanced cervical cancer

Tarrytown, n.y. and paris, jan. 28, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced the voluntary withdrawal of the supplemental biologics license application (sbla) for libtayo® (cemiplimab-rwlc) as a second-line treatment for patients with advanced cervical cancer.
REGN Ratings Summary
REGN Quant Ranking